239 related articles for article (PubMed ID: 21184228)
1. Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients.
Malagari K; Pomoni M; Spyridopoulos TN; Moschouris H; Kelekis A; Dourakis S; Alexopoulou E; Koskinas J; Angelopoulos M; Kornezos J; Pomoni A; Tandeles S; Marinis A; Rizos S; Kelekis D
Cardiovasc Intervent Radiol; 2011 Aug; 34(4):774-85. PubMed ID: 21184228
[TBL] [Abstract][Full Text] [Related]
2. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead.
Malagari K; Alexopoulou E; Chatzimichail K; Hall B; Koskinas J; Ryan S; Gallardo E; Kelekis A; Gouliamos A; Kelekis D
Abdom Imaging; 2008; 33(5):512-9. PubMed ID: 17938995
[TBL] [Abstract][Full Text] [Related]
3. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization.
Sadick M; Haas S; Loehr M; Elshwi M; Singer MV; Brade J; Schoenberg SO; Diehl SJ
Onkologie; 2010; 33(1-2):31-7. PubMed ID: 20164659
[TBL] [Abstract][Full Text] [Related]
4. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead.
Pomoni M; Malagari K; Moschouris H; Spyridopoulos TN; Dourakis S; Kornezos J; Kelekis A; Thanos L; Chatziioanou A; Hatjimarkou I; Marinis A; Koskinas J; Kelekis D
Hepatogastroenterology; 2012 May; 59(115):820-5. PubMed ID: 22024228
[TBL] [Abstract][Full Text] [Related]
5. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
[TBL] [Abstract][Full Text] [Related]
6. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles.
Padia SA; Shivaram G; Bastawrous S; Bhargava P; Vo NJ; Vaidya S; Valji K; Harris WP; Hippe DS; Kogut MJ
J Vasc Interv Radiol; 2013 Mar; 24(3):301-6. PubMed ID: 23380737
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients.
Malagari K; Chatzimichael K; Alexopoulou E; Kelekis A; Hall B; Dourakis S; Delis S; Gouliamos A; Kelekis D
Cardiovasc Intervent Radiol; 2008; 31(2):269-80. PubMed ID: 17999110
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
10. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741
[TBL] [Abstract][Full Text] [Related]
11. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis.
Pietrosi G; Miraglia R; Luca A; Vizzini GB; Fili' D; Riccardo V; D'Antoni A; Petridis I; Maruzzelli L; Biondo D; Gridelli B
J Vasc Interv Radiol; 2009 Jul; 20(7):896-902. PubMed ID: 19497762
[TBL] [Abstract][Full Text] [Related]
12. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis.
Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS
J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136
[TBL] [Abstract][Full Text] [Related]
13. [Transcatheter arterial chemoembolization with doxorubicin eluting beads in the treatment of hepatocellular carcinoma].
Sousa PF; Preto AS; Leão D; Madureira AM; Paquete J; Costa-Maia J; Vilares-Morgado P
Acta Med Port; 2011; 24(1):29-36. PubMed ID: 21672439
[TBL] [Abstract][Full Text] [Related]
14. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
15. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
16. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center.
Aliberti C; Carandina R; Lonardi S; Dadduzio V; Vitale A; Gringeri E; Zanus G; Cillo U
J Vasc Interv Radiol; 2017 Nov; 28(11):1495-1502. PubMed ID: 28927662
[TBL] [Abstract][Full Text] [Related]
17. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin.
Martin RC; Robbins K; Fagés JF; Romero FD; Rustein L; Tomalty D; Monaco R
Breast Cancer Res Treat; 2012 Apr; 132(2):753-63. PubMed ID: 22200868
[TBL] [Abstract][Full Text] [Related]
18. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
Odisio BC; Ashton A; Yan Y; Wei W; Kaseb A; Wallace MJ; Vauthey JN; Gupta S; Tam AL
J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion of doxorubicin-loaded microsphere for treatment of hepatocellular cancer: a multi-institutional registry.
Martin RC; Rustein L; Pérez Enguix D; Palmero J; Carvalheiro V; Urbano J; Valdata A; Kralj I; Bosnjakovic P; Tatum C
J Am Coll Surg; 2011 Oct; 213(4):493-500. PubMed ID: 21856182
[TBL] [Abstract][Full Text] [Related]
20. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
Song MJ; Chun HJ; Song DS; Kim HY; Yoo SH; Park CH; Bae SH; Choi JY; Chang UI; Yang JM; Lee HG; Yoon SK
J Hepatol; 2012 Dec; 57(6):1244-50. PubMed ID: 22824821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
